Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hirakata
Clinical trial register · Japan

Clinical Trials in Hirakata, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC13 Janssen Research & Development, LLC10 Eli Lilly and Company6 Bristol-Myers Squibb5 Pfizer4
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Hirakata

73 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Bristol-Myers Squibb
Phase 3
176
Miyakonojō, Hirakata, Yoshinogari-cho, Kanzaki-gun, Ōta-ku, Yokohama, Kanagawa
2026-10-02
Recruiting
Daiichi Sankyo
Phase 1/2
220
Kashiwa, Isehara, Yokohama, Hirakata, Chuo-ku, Koto-ku, Shinagawa-ku, Fukuoka
2026-09-17
Recruiting
Incyte Corporation
Phase 3
426
Bunkyō City, Chūō, Fukuoka, Fukushima, Hirakata, Kagoshima, Kashiwa-shi, Kobe
2026-09-08
Recruiting
Genmab
Phase 1
112
Hirakata, Chuo Ku, Koto-Ku
2026-08-13
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
Nagoya, Kita, Hirakata, Chūō, Kotoku, Osaka
2026-07-02
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1
80
Kashiwa, Maebashi, Niigata, Hirakata, Osaka, Sakai, Hidaka, Sunto-gun
2026-06-19
Recruiting
Novartis Pharmaceuticals
Phase 1
194
Hirakata
2026-05-28
Recruiting
Novartis Pharmaceuticals
Phase 1
208
Hirakata
2026-05-25
Recruiting
Exercise Training After Upper Gastrointestinal Cancer Surgery
NCT07561840Esophageal Cancer, Gastric Cancer (Diagnosis), Upper Gastrointestinal Cancer
Kansai Medical University
Not applicable
171
Hirakata
2026-05-15
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
Fukuoka, Hiroshima, Sapporo, Yokohama, Tokyo, Natori-shi, Niigata, Hirakata
2026-04-28
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Kobe, Nishinomiya, Sagamihara, Yokohama, Sendai, Hirakata, Sakai
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 1/2
240
Hirakata, Chuo-ku
2026-02-03
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Kashiwa, Sendai, Hirakata, Nagaizumi-cho, Bunkyo-ku
2026-01-30
Recruiting
Tokyo Women's Medical University
Phase 3
950
Akita, Chiba, Fukuoka, Fukushima, Fukuyama, Hamamatsu, Hirakata, Hiroshima
2026-01-28
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Chiba, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima
2025-12-22
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Bunkyō City, Hirakata, Kanazawa, Kobe, Sagamihara, Sunto Gun, Yokohama
2025-12-19
Recruiting
Pfizer
Phase 2/3
550
Hirakata, Nagaizumi-cho, Kotoku
2025-12-09
Recruiting
Janssen Research & Development, LLC
Phase 3
500
Hirakata, Kashiwa, Nagoya, Sapporo, Shinjuku, Sunto Gun, Tokyo
2025-12-03
Recruiting
Sanofi
Phase 3
124
Kitakyushu, Hiroshima, Sapporo, Kobe, Kahoku, Uchinada, Kanazawa, Nagaoka, Hirakata
2025-09-26
Recruiting
Bristol-Myers Squibb
Phase 2
182
Kashiwa, Sendai, Hirakata
2025-09-09
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
DrugsPalbociclib·Fulvestrant
Bristol-Myers Squibb
Phase 1
234
Kashiwa, Hirakata, Chuo-ku, Koto-ku
2025-08-01
Recruiting
Nippon Medical School
Phase 4
500
Chūō, Fukui, Fukuoka, Fukuyama, Hirakata, Kagoshima, Katsuura, Kawasaki
2025-08-01
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
404
Hirakata, Koto-ku
2025-07-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Matsuyama, Sapporo, Tsu, Hirakata, Sakai, Hidaka, Sunto-gun
2025-07-21
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
Kamogawa, Matsuyama, Hiroshima, Morioka, Kamakura, Tsu, Miyazaki, Hirakata
2025-07-18
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Ōbu, Narashino, Kawasaki, Tsu, Kurashiki, Hirakata, Kanzaki-gun, Shinjuku
2025-07-16
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Nagoya, Matsuyama, Sapporo, Kahoku-gun, Yokohama, Tsu, Naha, Hirakata
2025-06-30
Active, closed
Shanghai Henlius Biotech
Phase 2
26
Hirakata
2025-06-24
Recruiting
Aveir Leadless Pacemaker Japan PMS
NCT07106788Leadless Pacemaker
Abbott Medical Devices
Observational
304
Nagoya, Kitakyushu, Kawasaki, Sendai, Kurashiki, Hirakata, Osaka, Suita
2025-05-26
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Nagoya, Toyoake, Sapporo, Sendai, Hirakata, Izumo, Bunkyo, Chūō
2025-04-11
Recruiting
Eli Lilly and Company
Phase 3
700
Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kōtō City
2025-03-27
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Nagoya, Kashiwa, Hirakata, Koto
2025-02-27
Recruiting
Dianthus Therapeutics
Phase 3
256
Niigata, Kawasaki, Tsukuba, Kurashiki, Hirakata, Kawagoe, Ube
2025-02-10
Recruiting
Janssen Research & Development, LLC
Phase 3
750
Chiba, Chūōku, Hirakata, Hyōgo, Kitakyushu-shi, Nagoya, Osaka, Ōita
2025-01-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Kashiwa, Kitakyushu, Kawasaki, Yokohama, Hirakata, Sakai, Sunto-gun, Shimotsuga-gun
2024-10-21
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1
156
Kamogawa, Yoshida, Kurume, Sapporo, Hirakata, Mibu, Musashino, Fukuoka
2024-10-10
Recruiting
BeOne Medicines
Phase 1
310
Hirakata, Suntogun, Bunkyoku, Kotoku
2024-10-03
Recruiting
Bayer
Phase 3
444
Nagoya, Kashiwa, Sapporo, Himeji, Kobe, Sagamihara, Sendai, Hirakata
2024-08-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Toyoake, Tōon, Sapporo, Kobe, Kanazawa, Tsu, Sendai, Hirakata
2024-07-16
Recruiting
Eli Lilly and Company
Phase 3
510
Aichi, Chiba, Chūō, Fukui, Fukuoak, Fukuoka, Habikino-shi, Hirakata
2024-04-29
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Kashiwa, Matsuyama, Kitakyushu, Kobe, Kawasaki, Yokohama, Hirakata, Sakai
2024-04-03
Active, closed
Takeda
Phase 2
213
Sakura, Sapporo, Hirakata, Minato, Minato-ku, Mitaka, Fukuoka, Saga
2024-03-29
Recruiting
Takeda
Phase 2
268
Sapporo, Nishinomiya, Morioka, Sendai, Hirakata, Takatsuki-shi, Hamamatsu, Minato
2024-03-05
Recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugDocetaxel
Kyowa Kirin Co., Ltd.
Phase 1
101
Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Kobe, Yokohama, Hirakata
2024-01-18
Recruiting
Eli Lilly and Company
Phase 3
1,264
Asahikawa, Bunkyō City, Fukuoka, Hidaka, Himeji, Hirakata, Kanazawa, Kasama
2023-12-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Nagoya, Hirosaki, Kashiwa, Akashi, Kawasaki, Yokohama, Sendai, Hirakata
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
NCT06049212Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
DrugsSacituzumab tirumotecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
30
Nagoya, Kashiwa, Matsuyama, Yokohama, Hirakata, Nagaizumi-cho,Sunto-gun, Chuo-ku
2023-10-26
Recruiting
Incyte Corporation
Phase 1
570
Hirakata, Tokyo
2023-07-24
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Kurume, Akashi, Hirakata, Kashiwa, Nagoya, Ōsaka-sayama, Sapporo, Sendai
2023-06-01
Recruiting
Eli Lilly and Company
Phase 1/2
880
Fukuoka, Hirakata, Kōtō City, Kyoto
2023-04-17
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Bunkyō City, Chiba, Gifu, Gunma, Hirakata, Hitachi, Iruma-gun, Kamogawa
2023-03-29
Active, closed
Pfizer
Phase 1
148
Kashiwa, Hirakata
2022-11-30
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Bunkyō City, Chiba, Higashiibaraki-gun, Hirakata, Hyôgo, Iruma-gun, Kanagawa, Kanazawa
2022-10-25
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Bunkyō City, Chiba, Fukuoka, Gifu, Gunma, Hirakata, Hyōgo, Kamakura-shi
2022-10-13
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Chūōku, Himeji, Hirakata, Kanagawa, Kurashiki, Kurume, Matsusaka, Niigata
2022-08-05
Active, closed
Daiichi Sankyo
Phase 3
586
Akashi, Fukuoka, Hidaka, Hirakata, Iwakuni, Izumi, Kanazawa, Kōtoku
2022-07-08
Active, closed
BeOne Medicines
Phase 3
799
Matsuyama, Hiroshima, Sapporo, Kagoshima, Yokohama, KyotoShi, Okayama, Hirakata
2022-03-10
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Sapporo, Isehara, Tsu, Hirakata, Bunkyo, Minato, Chūō, Fukuoka
2022-01-14
Active, closed
Gilead Sciences
Phase 3
603
Asahikawa, Chūō, Fukui, Hirakata, Hiroshima, Hyōgo, Inzai, Iwakuni
2021-11-17
Active, closed
argenx
Phase 3
173
Hirakata, Iruma, Kanagawa, Kitakyushu, Shibukawa, Shimotsuke, Tama
2021-11-17
Active, closed
Daiichi Sankyo
Phase 3
605
Akashi, Chūōku, Fukuoka, Hidaka, Hirakata, Kanazawa, Kashiwa, Kōtoku
2020-12-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Nagoya, Kobe, Takarazuka, Yokohama, Hirakata, Takatsuki, Nakatogari, Fukuoka
2020-12-08
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Bunkyō City, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kishiwada, Kobe
2020-10-13
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Bunkyō City, Chūōku, Fukuoka, Himeji, Hirakata, Kanazawa, Kashiwa, Kurume
2020-09-30
Active, closed
PharmaEssentia
Phase 3
174
Tōon, Sagamihara, Tsu, Miyazaki, Hirakata, Sayama, Suita, Izunokuni
2020-08-25
Active, closed
Incyte Corporation
Phase 2
112
Bunkyō City, Chūō, Hirakata, Isehara, Kobe, Kyoto, Matsumoto-shi, Miyagi
2020-08-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Kurume, Kobe, Yokohama, Hirakata, Takatsuki, Fukuoka, Niigata, Osaka
2020-07-06
Active, closed
Janssen Pharmaceutical K.K.
Phase 2
31
Chūōku, Fukuoka, Hirakata, Matsuyama, Nagoya, Niigata, Sapporo
2020-04-07
Recruiting
National Cancer Center Hospital East
Phase 3
110
Chiba, Gifu, Hidaka, Hirakata, Hiroshima, Izumo, Kanazawa, Kashiwa
2019-10-01
Active, closed
Janssen Research & Development, LLC
Phase 1
701
Chūōku, Hirakata, Kashiwa, Kobe, Nagoya, Okayama, Shizuoka
2019-09-04
Active, closed
Intra-operative Pancreatoscopy in Patients With IPMN
NCT03729453Intraductal Papillary Mucinous Neoplasm
Boston Scientific Corporation
Observational
100
Hirakata
2019-03-20
Active, closed
Eli Lilly and Company
Phase 3
453
Amagasaki, Asahikawa, Bunkyō City, Fukuoka, Habikino, Hirakata, Hiroshima, Hyōgo
2014-10-03
Active, closed
Janssen Scientific Affairs, LLC
Observational
20,167
Hirakata, Hokkaido, Itabashi Ku, Kobe, Kurume, Matsumoto, Ōita, Takamatsu
2007-06-21
Rows per page Showing 1–73 of 73
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/hirakata

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 73 of those studies with a site in Hirakata.

How many clinical trials are recruiting in Hirakata?

45 of the 73 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hirakata), 73 studies
PhaseStudiesRecruitingShare
Phase 3392053.4%
Phase 1131017.8%
Phase 29512.3%
Phase 1/2556.8%
Observational314.1%
Phase 2/3222.7%
Not applicable111.4%
Phase 4111.4%

Most active sponsors

Lead sponsors with the most studies (Hirakata)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC138
Janssen Research & Development, LLC104
Eli Lilly and Company65
Bristol-Myers Squibb54
Pfizer43
Daiichi Sankyo31
Incyte Corporation32
BeOne Medicines21
Kyowa Kirin Co., Ltd.22
Novartis Pharmaceuticals22
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.